newsfilter
← Latest News
PR Newswire·

Mirati To Present Research at the AACR Annual Congress for Two Potentially First-in-Class Clinical Stage Programs

Preclinical data highlights MRTX0902 and MRTX1719 as potentially compelling targeted oncology treatment options SAN DIEGO, April 3, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ:MRTX), a commercial stage